• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Consumer Cyclical·NUC.AX
Share

Nuchev Limited Stocks

A$ 0.08Last Updated 26.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

A$ 8.83M

A$ 0.08
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nuchev Limited functions as a specialized health and nutrition company, responsible for the production, marketing, and distribution of infant formula and various nutritional items derived from goat milk. Its products are sold to consumers across Australia, China, and Vietnam. The firm offers a range of options under its Oli6 brand, including toddler nutrition, powdered goat milk, and general health and wellness goods. These products can be purchased through both conventional retail outlets and online e-commerce platforms. Nuchev Limited was established in 2013 and maintains its corporate headquarters in Melbourne, Australia.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of NUC.AX is 0.14 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 13:07

Hot Dogs vs. Squid. Will Netflix Save Its Business With a New Strategy?

27.10.2026 12:01

Top Stories This Morning: Intel to Acquire Quantum Startup, DoorDash in Talks for a $17 Billion Deal

27.10.2026 11:18

Stocks in South Korea and Japan surged on news of Anthropic's IPO. Is it time to buy?

27.10.2026 09:01

Anthropic's need for capital is growing. Will it receive an investment rating?

27.10.2026 08:00

No Room for Error: Citadel Securities Sees Economic Risks Posed by Investments in AI

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026